I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ISPOR 2026

We will be contributing to topics related to
-
08:00 PM
Duration 180mins Philadelphia, USA
Clinical and Economic Impact of Faricimab▼-Treated Diabetic Macular Edema: A Linked Analysis of Administrative Claims and IRIS Registry Data
Nicole Gidaya Bonine, Stella Ko, Xiaowu Sun, Jessica Clubb, Ayesha Ahmed, Bryan Moore, Laura Lupton, Dingwei Dai, Yi Liu, Yimin Wu, Blake A. Cooper
10:00 PM
Duration 180mins Philadelphia, USA
Impact of Lupus Nephritis Flares on Healthcare Utilization: A Retrospective Cohort Study in the United States between 2016 and 2025
Jiying Zou, Huong Trinh, Jesse Sussell, Shu Wang, Anisha M. Patel, William F. Pendergraft III, Lisa Lindsay
02:30 PM
Duration 180mins Philadelphia, USA
The Value Vocabulary: An Analysis of Societal Terms in Health Technology Assessment Decision Making
Jessica Moreira, Lori Yin, Chaim Simon Yunger, Jean-Éric Tarride
Duration 180mins Philadelphia, USA
Understanding the Impact and Burden of Menopause on Multiple Sclerosis Through a Targeted Literature Review
Jain, Divya, Ravelo Arliene, Abioye, Ibraheem, Pineda, Elmor D.
08:00 PM
Duration 180mins Philadelphia, USA
Novel therapies for relapsed/refractory mantle cell lymphoma post Bruton’s tyrosine kinase inhibitor: A targeted literature review
Weisman N, Lo-Rossi A, Lin C-W, Reyes C
Duration 180mins Philadelphia, USA
Cost-effectiveness of subcutaneous mosunetuzumab ▼ plus polatuzumab vedotin versus rituximab plus gemcitabine and oxaliplatin for United States (US) patients with autologous stem cell transplant-ineligible relapsed/refractory large B-cell lymphoma (LBCL)
Westin J, Rosettie KL, Masaquel A, Elsea D, Celik H, Seo M, Lai D, Lo-Rossi A, Flowers C
01:00 PM
Duration 180mins Philadelphia, USA
Dynamic Pricing in the Context of Cost-Effectiveness Modeling and Willingness-to-Pay Thresholds
Juha Raino Laine, Katherine Rosettie
Duration 150mins Philadelphia, USA
The total cost of care and budget impact of introducing mosunetuzumab ▼ plus polatuzumab vedotin for second-line or later (2L+) treatment of relapsed/refractory large B-cell lymphoma (LBCL) to a United States (US) health plan
Westin J, Elsea D, Rosettie KL, Masaquel A, Lo-Rossi A, Lai D, Flowers C
Duration 150mins Philadelphia, USA
Measuring Adherence to, and Persistence with, Advanced Therapy in US Patients with Lupus Nephritis in the Real-World Setting
Jesse Sussell, Anisha M. Patel, Achal Patel, Robert Schuldt, William F. Pendergraft III
Coming soon